Russia Performs 1st Implant of the World’s Only Approved Total Artificial Heart

60-Year-Old Woman is World’s 850th Total Artificial Heart Recipient

TUCSON, Ariz.--(BUSINESS WIRE)-- On March 23, the Bakoulev Scientific Center for Cardiovascular Surgery (BSCCS) in Moscow performed Russia’s first implant of the SynCardia temporary CardioWest™ Total Artificial Heart. The patient, a 60-year-old female suffering from biventricular heart failure, is the world’s 850th recipient of the Total Artificial Heart.

“There are currently 45 people waiting for a heart transplant at our hospital,” said Dr. Konstantin Shatalov, who assisted surgeon Prof. Leo Bockeria. “We selected this patient to receive the Total Artificial Heart as a bridge to transplant because without it, she’d have less than two weeks to live.”

The patient had suffered from dilated cardiomyopathy for more than three years. Walking more than 30 feet left her gasping for breath. Eventually, she was unable to eat or sleep. The patient says she hopes the Total Artificial Heart will allow her to experience the birth of her first grandchild, expected in less than a month.

“The Total Artificial Heart is leading edge technology,” said Prof. Bockeria, Head and Chairman of the BSCCS, who performed the Total Artificial heart implant. “Unlike a left ventricular assist device (LVAD), which helps the failing left ventricle, the Total Artificial Heart replaces both the left and right heart ventricles which are responsible for pumping blood. It is a true artificial heart.”

The surgery was proctored by Dr. Latif Arusoglu, an experienced Total Artificial Heart surgeon from the Heart & Diabetes Center NRW in Bad Oeynhausen, Germany. The BSCCS is the 29th hospital in the world to become a SynCardia Certified Center. Currently, there are SynCardia Certified Centers in the U.S., Canada, France, Germany, Italy, Sweden, Austria and now Russia.

According to the World Health Organization, cardiovascular diseases (CVD) are the main causes of death in Russia. In 2003, CVD was responsible for 56% of all deaths.

About SynCardia Systems, Inc.

SynCardia Systems, Inc. is the Tucson-based manufacturer of the world’s only FDA, Health Canada and CE approved Total Artificial Heart: the SynCardia temporary CardioWest™ Total Artificial Heart. There have been more than 850 implants of the Total Artificial Heart, accounting for more than 190 patient years of life on the device.

Originally used as a permanent replacement heart, the Total Artificial Heart is currently approved as a bridge to human heart transplant for people dying from end-stage biventricular failure. The Total Artificial Heart is the only device that provides immediate, safe blood flow of up to 9.5 L/min through both ventricles.

For additional information, please visit: http://www.syncardia.com
or follow SynCardia on Twitter – @SynCardia_News

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6241304&lang=en



CONTACT:

SynCardia Systems, Inc.
Don Isaacs
Vice President of Communications
Cell: 520-955-0660

KEYWORDS:   United States  Europe  North America  Arizona  Russia

INDUSTRY KEYWORDS:   Women  Surgery  Technology  Electronic Design Automation  Hardware  Health  Cardiology  Hospitals  Medical Devices  Manufacturing  Engineering  Consumer  General Health  Men

MEDIA:

Logo
 Logo
Photo
 Photo
During the first implant of SynCardia's Total Artificial Heart at the Bakoulev Scientific Center for Cardiovascular Surgery, it was hard to tell the doctors from the journalists. The operating room was filled TV news cameras filming the milestone surgery in Moscow. (Photo: Business Wire)

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.